key: cord-1025394-l3x2jjzd
authors: Tang, Kefu; Wu, Lei; Luo, Ying; Gong, Bo
title: Quantitative assessment of SARS‐CoV‐2 RNAemia and outcome in patients with coronavirus disease 2019
date: 2021-03-01
journal: J Med Virol
DOI: 10.1002/jmv.26876
sha: fc414e38d86b599e4468220abd37c1d05b637906
doc_id: 1025394
cord_uid: l3x2jjzd

The disease spectrum of coronavirus disease 2019 (COVID‐19) varies from asymptomatic infection to critical illness and death. Identification of prognostic markers is vital for predicting progression and clinical practice. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNA, known as RNAemia, has been detected in the blood. However, the potential clinical value of SARS‐CoV‐2 RNAemia remains unknown. We, therefore, conducted a meta‐analysis using a random‐effects model to estimate the pooled prevalence of SARS‐CoV‐2 RNAemia as well as summary strength of RNAemia in association with disease severity and unfavorable clinical outcomes. A total of 21 studies involving 2181 patients were included. SARS‐CoV‐2 RNAemia in COVID‐19 patients varied from 9.4% to 74.1%, with a pooled estimate of 34% (95% confidene interval [CI]: 26%–43%). Overall, SARS‐CoV‐2 RNAemia was associated with COVID‐19 severity with odds ratio (OR) of 5.43 (95% CI: 3.46–8.53). In addition, SARS‐CoV‐2 RNAemia was a significant risk factor for unfavorable clinical outcomes (OR = 6.54, 95% CI: 3.82–11.21). The summary OR was 4.28 (95% CI: 2.20–8.33) for intensive care unit (ICU) admission, 11.07 (95% CI: 5.60–21.88) for mortality. Furthermore, RNAemia was also a significant risk factor for invasive mechanical ventilation and multiple organ failure. SARS‐CoV‐2 RNAemia is associated with disease severity, ICU admission, death in COVID‐19, and may serve as a clinical predictor. More prospective trials in evaluating the potential of SARS‐CoV‐2 RNAemia as a prognostic indicator are necessary.

Coronavirus disease 2019 (COVID- 19) , originally reported from Wuhan, China, has spread globally in a very short period. 1 As of December 17, 2020, there were over 75 million confirmed cases and 1.6 million deaths. 2 Deep sequencing revealed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was responsible for the development of the COVID-19 pandemic. 3 Although most patients present mild-to-moderate symptoms, including fever, dry cough, and fatigue, 5%-10% progress to a severe or critical disease characterized by pneumonia and respiratory failure, and death occurred in 2%-5% of the cases. 4 SARS-CoV-2 RNA can be detected in nasopharyngeal (NP)/ throat swab, sputum, respiratory tract, peripheral blood, serum, feces, urine, and tear by polymerase chain reaction (PCR)-based methods. [5] [6] [7] [8] [9] Viral load by sample type is indicative of virus replication and clearance and is routinely used to monitor disease progression, response to antiviral agents, and relapse. 10 Since the lungs are most often affected and viral RNA is commonly detected in NP swabs, several studies have investigated viral loads in samples from the upper respiratory tract as a biomarker for severity assessment. Zou et al.reported that the viral load was similar among asymptomatic patients and symptomatic patients. 11 Metagenomic sequencing of NP swabs from COVID-19 patients with different severity indexes suggested that increased SARS-CoV-2 RNA detection is associated with the early stages rather than disease severity. 12 These results suggest that viral load in respiratory samples cannot be considered as a prognostic indicator for severe or critically ill cases. Currently, the relationship between viral load dynamics in samples from extrapulmonary sites (fecal, tear, and urinary samples) and disease severity remains unknown.

Recently, coagulopathy has been reported in severe COVID-19 cases, 13, 14 implying the spread of SARS-CoV-2 within extrapulmonary sites via blood flow. In addition to the difficulty of SARS-CoV-2 virus culture from the blood, 15 serum SARS-CoV-2 nucleic acid (RNAemia) represents a practical and powerful approach to evaluate the impact of viral load dynamics on disease severity in extrapulmonary sites. Increasing evidence addressing SARS-CoV-2

RNAemia and disease progression are available; a definite conclusion

has not yet been reached. Therefore, we aimed to establish a comprehensive picture of the association between RNAemia and disease severity as well as unfavorable outcomes, including intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and death.

RNAemia was defined as the presence of viral RNA, above the technical limits of detection of PCR-based assays, in the blood, serum, or plasma.

To identify studies addressing SARS-CoV-2 RNAemia and outcome in patients with COVID-19, a systematic literature search from December 1, 2019 to December 24, 2020 was conducted in PubMed, MedRxiv, BioRxiv, Embase, Cochrane Library, and Chinese National Knowledge Infrastructure without any restriction. The search term included keywords relevant to SARS-CoV-2 RNAemia (e.g., "SARS-CoV-2 RNAemia," "RNAemia," and "viral load") in combination with words related to the clinical outcome (e.g., "severity," "mild," "moderate," "severe," "critical," "IMV," "Invasive mechanical ventilation," "ICU," "intensive care unit," "death," and "mortality") and the blood ("whole blood," "serum,"

and "plasma"). The titles and abstracts from retrieved articles were screened to determine their relevance and the references from included studies were scrutinized and hand-searched for additional eligible studies.

Eligible studies were required to meet the following criteria: (1) clinical study evaluated the association between SARS-CoV-2 F I G U R E 1 Flowchart of study selection RNAemia and COVID-19 severity or outcomes; (2) original articles reported independent data; (3) reported relative risks with 95% confidence intervals (CIs) or sufficient information for effect size calculation. Studies with fewer than 10 patients; studies only examined samples other than the blood (e.g., digestive tract, feces, and respiratory samples) were excluded.

Information with regard to authorship, publication year, country, study design, numbers of patients, age, gender distribution, SARS-CoV-2 RNAemia rate, unfavorable outcomes (ICU admission and/or death), severity (mild, moderate, severe, and critical illness), IMV, multiple organ failure (organ ≥ 2), viral RNAemia, SARS-CoV-2 detection method, variables adjusted for in the multivariable analysis, and risk estimates with corresponding 95% CIs was summarized independently by two reviewers according to a fixed protocol.

Inconsistency from data reports was resolved by further discussion among all authors through consensus.

The strength of the association between the presence of SARS-CoV-2 RNAemia and clinical severity or outcomes was estimated using odds ratios (ORs), with the corresponding 95% CIs. Hazard ratio (HR), relative risk (RR), and rate ratio were treated as equivalent estimates of OR since the unfavorable outcome of patients with COVID-19 is relatively rare. 16 The association of SARS-CoV-2 RNAemia was first compared between different clinical severity (mild/moderate vs. severe/critical).

Then we examined the association between SARS-CoV-2 RNAemia and adverse clinical outcomes (ICU admission and/or death).

Stratified meta-analyses based on country (East Asian vs. Western country) and study design (prospective vs. retrospective) Characteristics of the included studies are shown in Table 1 .

The positive rate of serum SARS-CoV-2 viral RNA varied from 9.4%

to 74.1%, with a pooled estimate of 34% (95% CI: 26%-43%, Figure 2 ). Significant heterogeneity (p < 10 −5 , I 2 = 95.6%) was detected among included studies, indicating a significant difference across different studies. Overall, SARS-CoV-2 RNAemia was associated with COVID-19 severity with OR of 5.43 (95% CI: 3.46-8.53, p < 10 −5 ; Figure 3 ). The data on age distribution were reported in four studies; individuals with RNAemia were significantly older than those with undetectable SARS-CoV-2 RNA in a combined analysis (p < .01). When stratified by study country and study design, significant results were maintained (Table 2 ).

We found that unfavorable clinical outcomes are significantly more likely to occur in patients with SARS-CoV-2 RNAemia compared with those with undetectable SARS-CoV-2 RNA (OR = 6.54, 95% CI:

3.82-11.21, p < 10 −5 ; Figure 4 ). ORs for SARS-CoV-2 RNAemia positivity were 4.28 (95% CI: 2.20-8.33; Figure 5 ) for ICU admission and 11.07 (95% CI: 5.60-21.88; Figure 6 ) for all-cause mortality.

When analyzed according to country and study design, significant associations were detected almost in all comparisons ( 

There was statistical heterogeneity in comparison (Table 2 ) and the study by Lei et al. was identified as the main source of betweenstudies heterogeneity in sensitivity analyses. As for limited data, meta-regression could not be performed to assess the correlation between SARS-CoV-2 RNAemia and disease severity or clinical outcomes.

A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual data set to the pooled ORs, and the corresponding pooled ORs were not qualitatively altered. No publication bias (p > .05 for all) was observed for this overall metaanalysis ( Figures S2 and S3 ).

To our knowledge, this is the first meta-analysis to explore the as- There is inconsistency in the positive rate of SARS-CoV-2

RNAemia among published data, whereas some authors reported 0%-1% of RNAemia. 1, 11 Here are several explanations to interpret the abovementioned phenomenon. First, clinical characteristics (e.g., the number of patients with severe/critically illness, and age) may attribute to these different results since SARS-CoV-2 RNAemia occurred more frequently in older age and severe cases. Second, differences in sample collection protocols (e.g., at hospital admission, after confirmed COVID-19 cases, several days before or after the NP collection or symptom) may also have affected the results, as an optimal period for blood sampling remain unknown. RNAemia as a prognostic marker for predicting progression and outcomes of COVID-19. Second, our results were mainly based on unadjusted estimates. Ideally, we would like to pool individual-level data and conduct a more precise analysis, which could be adjusted for other covariants, such as age, obesity, and other common comorbidities, including cancer, hypertension, diabetes, and cardiovascular diseases. Third, subgroup meta-analyses were performed on the basis of a fraction of all the possible data, so selection bias may have occurred.

In summary, the findings of this study revealed that SARS-CoV-2

RNAemia is a significant risk factor for disease severity and adverse outcomes in COVID-19, particularly for ICU admission and death.

These results suggest that RNAemia may serve as a clinical scoring component for risk stratification, and SARS-CoV-2 RNAemia evaluation would be crucial for COVID-19 patients. To confirm these findings, future studies should involve a prospective design, strict selection of cases, testing protocols, and larger studies of diverse populations.

China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China

COVID-19 Dashboard by the Center for Systems Science and Engineering

RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak

Clinical characteristics of coronavirus disease 2019 in China

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Urinary viral shedding of COVID-19 and its clinical associations: a systematic review and meta-analysis of observational studies

Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis

Detection of SARS-CoV-2 in different types of clinical specimens

Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province China

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Metagenomic nextgeneration sequencing of nasopharyngeal specimens collected from confirmed and suspect COVID-19 patients

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies

Meta-analysis in clinical trials

Measuring inconsistency in meta-analyses

Bias in metaanalysis detected by a simple, graphical test

Operating characteristics of a rank correlation test for publication bias

Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19

SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load

High frequency of SARS-CoV-2 RNAemia and association with severe disease

Relationship between serum SARS-CoV-2 nucleic acid (RNAemia) and organ damage in COVID-19 patients: a cohort study

Highly sensitive quantification of plasma severe acute respiratory syndrome coronavirus 2 RNA sheds light on its potential clinical value

SARS-CoV-2 RNA in plasma is associated with ICU admission and mortality in patients hospitalized with COVID-19

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

et alKey to successful treatment of COVID-19: accurate identification of severe risks and early intervention of disease progression medRxiv

Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients

Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity

Viable circulating endothelial cells and their progenitors are increased in Covid-19 patients

RNAemia corresponds to disease severity and antibody response in hospitalized COVID-19 patients

SARS-CoV-2 RNAemia with higher nasopharyngeal viral load is strongly associated with severity and mortality in patients with COVID-19

Temporal kinetics of RNAemia and associated systemic cytokines in hospitalized COVID-19 patients

SARS-CoV-2 RNAaemia predicts clinical deterioration and extrapulmonary complications from COVID-19

Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in serum for microbiological diagnosis

Factors associated with clinical outcomes in patients with coronavirus disease 2019 in Guangzhou

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Viral load kinetics of MERS coronavirus infection

Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis, and meta-regression analysis

Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and metaanalysis

Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and metaanalysis

Immune alterations during SARS-CoV-2-relatedacute respiratory distress syndrome

Multiorgan and renal tropism of SARS-CoV-2

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

A dynamic COVID-19 immune signature includes associations with poor prognosis

Additional Supporting Information may be found online in the supporting information tab for this article.How to cite this article: Tang